We designed the EURAMOS-1 trial to investigate whether intensified .. and a normal creatinine concentration for their age as per protocol. EURAMOS-1, an international randomised study for osteosarcoma: Results from Pre-operative chemotherapy was completed according to protocol in 94%. The EURAMOS 1 trial is a multimodal therapy of osteosacoma with precluding treatment with protocol chemotherapy (for example HIV.
|Published (Last):||13 June 2008|
|PDF File Size:||9.2 Mb|
|ePub File Size:||9.22 Mb|
|Price:||Free* [*Free Regsitration Required]|
Or filter your current search. Of those patients, one Good Responder had worst toxicity of grade 1; one poor responder had worst euraamos of grade 3 and one person with unknown histological response had a worst toxicity of grade 4.
Teot38 M. Long-term event data were sought in all patients, regardless of randomisation.
Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. The single new treatment which has emerged, mifamurtide MTP-PEhas been the subject of considerable controversy and its availability varies internationally, due to disagreements about interpretation of the available clinical data and cost.
Page Not Found | MRC Clinical Trials Unit at UCL
There was some variability in proportion randomised between groups: Gene Ontology GO Terms. We were unable to open EURAMOS-1 in some countries that wished to participate either because of regulatory constraints or insufficient funding.
There were limits to the accessibility of the trial for osteosarcoma patients. How does Europe PMC derive its citations network? Osteosarcoma therapy was revolutionised by the introduction of adjuvant combination chemotherapy, in the s, but has improved little since.
Page Not Found
The international studygroup recommands until further notice to treat all patients with the standardarm MAP. The role of interferons in the potocol of osteosarcoma.
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: Gorlick19 G. Good histological response, assessed in the resected tumour, has been associated with improved survival [ 3 — 5 ]. While the link between increased toxicity and improved survival from osteosarcoma remains to be unravelled [ 26 ], future approaches must look to reduce this eiramos as well as improve efficacy.
Deffenbaugh13 C. Supplementary Material Supplementary Data: Dhooge14 M. Smeland4, 5 G. With patients with resectable osteosarcoma randomised, it doubled the size of the previous largest RCT in this population and accrual was completed in around 6 years.
The cost of seeking cure is exceptionally high as patients receive particularly complex and toxic chemotherapy regimens, plus disabling surgery. Chief investigator of the german study-group Prof.
University Hospital Ghent, Gent, Belgium. Protkcol was the first publicly-funded pan-European clinical trial to be activated after European countries implemented the European Clinical Trials Directive, which created new challenges [ 23 ]. Additional objectives were to facilitate biological research in osteosarcoma, more rapidly identify new therapeutic approaches and develop a common understanding and methodologies for staging, pathology and other aspects of disease management [ 2 ].
Main objectives To examine in a randomized trial, whether the addition of ifosfamide and etoposide IE to post-operative chemotherapy with cisplatin, doxorubicin and methotrexate improves event-free survival for patients with resectable osteosarcoma and a poor histological response to 10 weeks of pre-operative chemotherapy. Worst pre-operative MAP toxicity. Patients were randomised after surgery.
Nagarajan34 R. Registered patients were offered randomisation when also had: Commencing Marchpatients were registered from centres across 17 countries.